Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Promosome

Promosome

Promosome, LLC: A US-based biotech firm enhancing protein synthesis and gene therapy solutions.

: 11
: Private company
: 2003
: New York City, NY, USUnited States

Promosome, LLC provides biotechnology solutions. The Company offers a technical platform for enhancement of protein synthesis for increasing

protein production capacity, cell line development speed, development of DNA vaccines, and gene therapy. Promosome operates in the United States.

Similar Companies

Promontory Therapeutics

promontorytx.com

Porosome Therapeutics

porosome.com

Multispan

multispaninc.com

Protein Foundry

proteinfoundry.com

Permeon Biologics

permeonbio.com

Prosetta

prosetta.com

PackGene Biotech

packgene.com

Promentis Pharmaceuticals

Prometheon Pharma

Promiliad Biopharma

promiliad.com

Proteotech

Strm.Bio

strm.bio

Remix Therapeutics

remixtx.com

Synvivia

synvivia.com

Dnalite Therapeutics

ImCare Biotech

Promakhos Therapeutics

promakhos.com

Promethera Biosciences

promethera.com

Rbio

rbio.online

Transomic Technologies

Quick Facts

Who are Promosome's competitors?

Companies similar to Promosome include Promontory Therapeutics, Porosome Therapeutics, Multispan and Protein Foundry.

When was Promosome founded?

Promosome was founded in 2003.

Where is Promosome's headquarters located?

Promosome's headquarters is located in New York City, NY, US.

When was Promosome's last funding round?

Promosome's most recent funding round was for $4.1M (USD) in January 2011.

How much disclosed funding has Promosome raised?

As of Jan 25, 2011, Promosome has disclosed funding of $13.7M (USD). Undisclosed round amounts are excluded.

How many employees does Promosome have?

Promosome has 11 employees as of Feb 4, 2024.

Classification

Ownership: Private
Technology: Biotech
Geographic Exposure: United States

Revenue: Recurring
Software
Customer: Enterprise
Main Product: Gene Therapy
Protein Synthesis

Also Known As: Promosome LLC

Headquarters: 369 Lexington Avenue
17th Floor
New York City, NY, 10017
US

NAICS: 540000Professional, Scientific, and Technical Services
541500Computer Systems Design and Related Services
541000Professional, Scientific, and Technical Services
541510Computer Systems Design and Related Services
541511Custom Computer Programming Services
SIC: 7300Business Services
7370Computer Programming, Data Processing, And Other Computer Related
7371Computer Programming Services
ISIC: 8890Other social work activities without accommodation
Industry: —Bioinformatics Organizations
—Software Companies

Show 12 more industry codes

NAICS: 513200Software Publishers
624000Social Assistance
624100Individual and Family Services
624190Other Individual and Family Services
510000Information
620000Health Care and Social Assistance
513000Publishing Industries
513210Software Publishers
SIC: 8320Individual And Family Social Services
8322Individual And Family Social Services
8300Social Services
7372Prepackaged Software